0.5700
+0.0100
+(1.79%)
At close: January 24 at 3:16:00 PM EST
Breakdown
TTM
7/31/2024
7/31/2023
7/31/2022
7/31/2021
Operating Expense
29,979.8800
33,330.0760
23,272.2640
15,285.5530
6,972.3440
Operating Income
-29,979.8800
-33,330.0760
-23,272.2640
-15,285.5530
-6,972.3440
Net Non Operating Interest Income Expense
110.2530
288.0180
891.2130
135.7520
-75.4050
Other Income Expense
13,149.9310
28,110.5100
2,078.6570
-11,689.1020
-6,768.4510
Pretax Income
-16,719.6960
-4,931.5480
-20,302.3940
-26,838.9030
-13,816.2000
Net Income Common Stockholders
-16,595.1840
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Diluted NI Available to Com Stockholders
-2,313.1060
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Basic EPS
-0.89
-0.29
-1.30
-1.73
-0.09
Diluted EPS
-0.89
-0.29
-1.30
-1.73
-0.09
Basic Average Shares
19,119.7600
16,454.9320
15,619.6760
15,494.0910
4,519.5790
Diluted Average Shares
19,119.7600
16,454.9320
15,619.6760
15,494.0910
4,519.5790
Total Operating Income as Reported
-29,979.8800
-33,330.0760
-23,272.2640
-15,288.9410
-6,973.4980
Rent Expense Supplemental
--
--
--
--
11.9390
Total Expenses
29,979.8800
33,330.0760
23,272.2640
15,285.5530
6,972.3440
Net Income from Continuing & Discontinued Operation
-16,595.1840
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Normalized Income
-29,923.1400
-33,008.4860
-22,381.0510
-15,149.8010
-7,047.7490
Interest Income
110.2530
288.0180
891.2130
136.7310
3.1490
Interest Expense
--
--
--
0.9790
78.5540
Net Interest Income
110.2530
288.0180
891.2130
135.7520
-75.4050
EBIT
-29,979.8800
-33,330.0760
-23,272.2640
-26,837.9240
-13,737.6460
EBITDA
-29,873.1440
-33,246.1790
-23,256.9930
-26,822.6520
-13,722.3900
Reconciled Depreciation
106.7360
83.8970
15.2710
15.2720
15.2560
Net Income from Continuing Operation Net Minority Interest
-16,595.1840
-4,791.4660
-20,302.3940
-26,838.9030
-13,816.2000
Total Unusual Items Excluding Goodwill
13,327.9560
28,217.0200
2,078.6570
-11,689.1020
-6,768.4510
Total Unusual Items
13,327.9560
28,217.0200
2,078.6570
-11,689.1020
-6,768.4510
Normalized EBITDA
-43,201.1000
-61,463.1990
-25,335.6500
-15,133.5500
-6,953.9390
7/31/2021 - 8/13/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MDNA.TO Medicenna Therapeutics Corp.
1.3400
-1.47%
APS.TO Aptose Biosciences Inc.
0.3000
+1.69%
ONC.TO Oncolytics Biotech Inc.
1.1300
-3.42%
FRX.TO Fennec Pharmaceuticals Inc.
9.00
+13.92%
MBX.TO Microbix Biosystems Inc.
0.4850
-3.00%
DBV.PA DBV Technologies S.A.
0.8750
+1.27%
ATXS Astria Therapeutics, Inc.
7.41
-3.52%
1GDA.F Zevra Therapeutics, Inc.
7.65
-1.29%
HQ1.MU Oruka Therapeutics Inc. R
12.20
0.00%
ORN.F Oryzon Genomics S.A.
1.4100
-3.16%